Mast cells and tumors;Mastocytes et tumeurs

Revue Francaise d'Allergologie et d'Immunologie Clinique

Volumn 37, Issue 7, 1997, Pages 881-888

  Ponvert, C ^a   Galoppin, L ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Cancer; Factor ; Histamine; Inflammation; Mast cells; Prostaglandins; Tumor necrosis

Indexed keywords

ARTICLE; CANCER; CANCER IMMUNOLOGY; FRANCE; HISTAMINE RELEASE; HUMAN; IMMUNOTHERAPY; MAST CELL; MAST CELL DEGRANULATION;

EID: 0031407227     PISSN: 03357457     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0335-7457(97)80013-5     Document Type: Article

References (142)

1. Amlot P.L., Slaney J., Brown R. - Atopy. A favourable pronostic factor for survival in Hodgkin's disease. Br. J. Cancer, 1983, 48, 209-215.
2. Artz E., Costas M., Finfielman S., Nahmod V.E. - Serotonin inhibition of tumor necrosis factor-α synthesis by human monocytes. Life Sci., 1991, 48, 2557-2562.
3. Asboe-Hansen G., Levi H., Wegelius O. - Mast cells and intercellular mucopolysaccharides in Rous fowl sarcoma I. Cancer Res., 1957, 17, 792-796.
4. Aune T.M., Golden H.W., McGrath K.M. - Inhibitors of serotonin synthesis and antagonists of serotonin 1A receptors inhibit T lymphocyte function in vitro and cell-mediated immunity in vivo. J. Immunol., 1994, 153, 489-498.
5. Barna B.P. - Tumor-enhancing effects of cimetidine. Oncology, 1983, 40, 43-45.
6. Bartholeyns J., Bouclier M. - Involvement of histamine in growth of mouse and rat tumors. Antitumoral properties of monofluoromethylhistidine, an enzyme-activated irreversible inhibitor of histidine-decarboxylase. Cancer Res., 1984, 44, 639-645.
7. Bartholeyns J., Fozard J.R. - Role of histamine in tumor development. Tr. Pharmacol. Sci., 1985, 67, 123-125.
8. Benett J.A. - Cimetidine blocks the development of tumor-induced suppressor T cell activity. Int. J. Immunopharmacol., 1982, 4, 280.
9. Benyon R.C., Bissonnette E.Y., Befus A.D. - Tumor necrosis factor-α-dependent cytotoxicity of human skin mast cells is enhanced by anti-IgE antibodies. J. Immunol., 1991, 147, 2253-2258.
10. Bloksma N., Kuper C.F., Hofhuis F.M.A., Willers J.M.N. - Role of vasoactive amines in the antitumor activity of endotoxin. Immunopharmacology, 1984, 7, 201-209.
11. Boranic M., Pericic D., Poljak-Blazi M., Sverko V. - Suppression of the immune response by drugs interfering with the metabolism of serotonin. Experientia, 1984, 40, 1153-1155.
12. Bossa R., Benvenuti C., Cantoni V., Galatulas I. - H2 antagonists and therapy of rodent tumors. Cancer Lett., 1983, 20, 231-234.
13. Bowers H.M., Mahapatro R.C., Kennedy J.W. - Numbers of mast cells in the axillary lymph nodes of breast cancer patients. Cancer, 1979, 43, 568-573.
14. Braun D.P., Harris J.E. - Abnormal indomethacin-sensitive suppression in peripheral blood mononuclear cells of cancer patients restricts augmentation by IL-2. J. Biol. Resp. Modif., 1984, 3, 533-540.
15. Bréau J.L. - Régressions et freinages de croissance des métastases pulmonaires de cancers humains induits par le piroxicam, un inhibiteur de la synthèse des prostaglandines. Bull. Cancer, 1989, 76, 321-328.
16. Burtin C., Scheinmann P., Salomon J.C. et al. - Increased tissue histamine levels in tumor-bearing mice and rats. Br. J. Cancer, 1981, 43, 684-688.
17. Burtin C., Scheinmann P., Salomon J.C. et al. - The influence of intraperitoneal injections of histamine on tumor growth in fibrosarcoma-bearing mice. Cancer Lett., 1981, 12, 195-201.
18. Burtin C., Scheinmann P., Salomon J.C. et al. - Decrease in tumor growth by injections of histamine or serotonin in fibrosarcoma-bearing mice. Influence of H1 and H2 receptors. Br. J. Cancer, 1982, 45, 54-60.
19. Burtin C., Noirot C., Paupe J. et al. - Decreased blood histamine levels in patients with solid malignant tumors. Br. J. Cancer, 1983, 47, 367-372.
20. Burtin C., Scheinmann P., Noirot C. et al. - Combination of cimetidine with other drugs for treatment of cancer. N. Engl. J. Med., 1983, 308, 591-592.
21. v, W/+ and +/+ mice. J. Natl. Canc. Inst., 1985, 74, 671-674.
22. Burtin C., Noirot C. - Histaminémie, marqueur de l'évolutivité néoplasique. Son intérêt dans la surveillance des cancers. Le Biologiste, 1986, XX, 233-237.
23. Burtin C., Noirot C., Scheinmann P. et al. - Clinical improvement in advanced cancer disease after treatment combining histamine and H2-antihistaminics (ranitidine or cimetidine). Eur. J. Cancer Clin. Oncol., 1988, 24, 161-167.
24. Bykowskaya S.N., Bolvacheva A.V., Kiselevsky M.V. et al. -Platelet-mediated cytotoxicity and its enhancement by platelet-activating factor. Biomed. Pharmacother., 1991, 45, 279-288.
25. Caignard A., Martin M., Reisser D. et al. - Effects of cimetidine and indomethacin on the growth of dimethylhydrazine-induced or transplanted intestinal cancers in the rat. Br. J. Cancer, 1984, 50, 661-665.
26. Cawley E.P., Hoch-Ligeti C. - Association of tissue mast cells and skin tumors. Arch. Dermatol., 1961, 83, 146-149.
27. Chao T.Y., Chu T.M. - Effect of indomethacin on tumor-infiltrating lymphocytes of a spontaneously developed murine mammary adenocarcinoma. Cancer Immunol. Immunother., 1989, 30, 158-164.
28. Colin-Jones D.G., Langman M.J.S., Lawson D.H. et al. -Postmarketing surveillance of the safety of cimetidine : 10-year mortality report. Gut, 1992, 33, 1280-1284.
29. Collins M., Hellmann K. - Histamine receptor antagonism and antitumor activity. Br. J. Cancer, 1982, 46, 817-820.
30. Correnti M., Sanchez M., Chacon R.S. - A role for anaphylactic sensitization in tumor control. Int. Arch. Allergy Appl. Immunol., 1985, 76, 20-24.
31. Cramer W., Simpson W.L. - Mast cells in experimental skin carcinogenesis. Cancer Res., 1944, 4, 601-616.
32. Csaba G., Törö I., Acs T., Kiss F.I. - The behaviour of the thymus in conditions associated with tissue proliferation. Acta Morphol. Acad. Sci. Hung., 1960, 9, 187-196.
33. Csaba G., Horwath C., Mold K. - Genesis and functions of mast cells. Mast cell and plasmocyte reaction to induced homologous and heterologous tumors. Br. J. Cancer, 1961, 15, 327-335.
34. Csaba G., Forgacs A. - Behaviour of mast cells in the skin of mice treated with benzopyrene. Acta Morphol. Acad. Sci. Hung., 1970, 18, 17-22.
35. Dabbous M.K., Walker R., Haney L. et al. - Mast cells and matrix degradation at sites of tumor invasion in rat mammary adenocarcinoma. Br. J. Cancer, 1986, 54, 459-465.
36. Dabbous M.K., Walker R., Haney L. et al. - Mast-mediated effectors of tumor invasion. Role of mast cells in matrix degradation. Clin. Exp. Metastasis, 1986, 4, 141-152.
37. De Cidre L.L., de Lustig E.S. - Mast cell kinetics during tumor growth. Tumor Biol., 1990, 11, 196-201.
38. Donhuijsen K., Sastry M., Völker B., Leder L.D. - Mast cell frequency in soft tissue tumors. Relation to type and grade of malignancy. Pathol. Res. Pract., 1992, 188, 61-66.
39. Dunn M.R., Montgomery O.B. - A study of the relationship of mast cells to carcinoma in situ of the uterine cervix. Lab. Invest., 1957, 6, 542-546.
40. Edelman A.S., Robinson M.E., Sanchez P., Thorbeck G.J. - Suppressor T cells with histamine type II receptors in chickens bearing chemically-induced fibrosarcomas. Cell. Immunol., 1987, 110, 321-337.
41. Eisenthal A., Monselise J., Zinger R., Adler A. - The effect of cimetidine on PBL from healthy donors and melanoma patients. Augmentation of T cell responses to TCGF, mitogens and alloantigens, and of TCGF production. Cancer Immunol. Immunother., 1986, 21, 141-147.
42. Eriksson N.E., Holmen A., Hogstedt B. et al. - Cancer incidence in a cohort examined for allergy. Allergy Clin. Immunol. News, 1994, S2, 653.
43. 1. Prostaglandins Med., 1981, 7, 195-198.
44. Fantone J.C., Kunkel S.L., Weingarten B. - Inhibition of carrageenin-induced rat footpad edema by systemic treatment with prostaglandins of the E series. Biochem. Pharmacol., 1982, 31, 1126-1128.
45. Farram E., Nelson D.S. - Mouse mast cells as antitumor effector cells. Cell. Immunol., 1980, 55, 294-301.
46. Fischerman E.W. - Does the allergic diathesis influence malignancy? J. Allergy, 1960, 31, 74-78.
47. Fisher B., Fisher E.R. - Local factors affecting tumor growth. I : effects of tissue homogenates. Cancer Res., 1963, 23, 1651-1657.
48. Fisher E.R., Fisher N. - Role of mast cells in tumor growth. Arch. Pathol., 1965, 79, 185-191.
49. Fisher E.R., Sass R., Watkins G. et al. - Tissue mast cells in breast cancer. Breast Cancer Res. Treat., 1985, 5, 285-291.
50. Flödgren P. - Influence of human leukocyte interferon (HuIFN-α/Le) and cimetidine on the proliferation of cultured melanoma cells in vitro. Anticancer Res., 1985, 5, 527-532.
51. Flynn E.A., Schwartz J.L., Shklar G. - Sequential mast cell infiltration and degranulation during experimental carcinogenesis. J. Cancer Res. Clin. Oncol., 1991, 117, 115-122.
52. Folkman J. - Commentary: regulation of angiogenesis. A new function for heparin. Biochem. Pharmacol., 1985, 34, 905-912.
53. Fray A., Lespinats G., Scheinmann P. et al. - Selective increased tissue histamine levels in tumor-bearing rodents. Agents Actions, 1983, 13, 230-233.
54. Fray A., Lespinats G., Scheinmann P. et al. - In vivo and in vitro antitumour activity of dimaprit. Agents Actions, 1985, 16, 284-286.
55. Frieri F., Metcalfe D.D. - Analysis of the effect of mast cell granules on lymphocyte blastogenesis in the absence or presence of mitogens. Identification of heparin as a granule-associated suppressor factor. J. Immunol., 1983, 131, 1942-1948.
56. Fujii T.T. - Significance of suppressor macrophages for immunosurveillance of tumor-bearing mice. J. Natl. Cancer Inst., 1987, 78, 509-517.
57. Fulton A.M. - Effects of indomethacin on the growth of cultured mammary tumors. Int. J. Cancer, 1984, 33, 375-379.
58. Fulton A.M. - Interactions of natural effector cells and prostaglandins in the control of metastasis. J. Natl. Cancer Inst., 1987, 78, 735-741.
59. Galoppin L., Raynaud F., Ponvert C. et al. - Tissue histamine levels and mast cell numbers in tumor-bearing mice. Agents Actions, 1984, 14, 494-496.
60. Galoppin L., Ponvert C. - L'histamine. Rev. franc. Allergol., 1997, 37, 865-880.
61. Ghiara P., Boraschi D., Villa L. et al. - In vitro generated mast cells express natural cytotoxicity against tumor cells. Immunology, 1985, 55, 317-324.
62. Goerner A. - Influence of anticlotting agents on transplantation and growth of tumor tissues. J. Lab. Clin. Med., 1931, 16, 369-372.
63. Gorczynski R.M., Kennedy M., Ciampi A. - Cimetidine reverses tumor growth enhancement of plasmacytoma tumors in mice demonstrating conditioned immunosuppression. J. Immunol., 1985, 134, 4261-4266.
64. Graham R.M., Graham J.B. - Mast cells and cancer of the cervix. Surg. Gynecol. Obstet., 1966, 123, 3-7.
65. Hannant D., James K., Bolton R.E. et al. - Cimetidine and therapy of rodent tumours. Br. J. Cancer, 1982, 45, 613-614.
66. Hellstrand K., Hermodsson S. - Histamine H2 receptor mediated regulation of human natural killer cell activity. J. Immunol., 1986, 137, 656-661.
67. Hellstrand K., Hermodsson P. - Differential effect of histamine receptor antagonists on human natural killer cell activity. Int. Arch. Allergy Appl. Immunol., 1987, 84, 247-255.
68. + NK cells, accessory monocytes, and 5-HT1A receptors. Cell. Immunol., 1990, 127, 199-214.
69. + natural killer (NK) cells is required for histamine H2 receptor-mediated NK cell activation. Scand. J. Immunol., 1990, 31, 631-638.
70. Hellstrand K., Hermodsson S. - Synergistic NK cell activation by histamine and interleukin-2. Int. Arch. Allergy Appl. Immunol., 1990, 92, 379-387.
71. Henderson W.R., Chi E.Y., Jong E.C., Klebanoff S.J. - Mast cell-mediated tumor cell cytotoxicity. Role of the peroxidase system. J. Exp. Med., 1981, 153, 520-533.
72. Hirai N., Hill N.O., Motoo Y., Osther K. - Effects of cimetidine on various biological activities of human leukocyte IFN and on IFN production in lymphocytes.Tohoku J. Exp. Med., 1985, 147, 199-212.
73. Hirai N., Hill N.O., Motoo Y., Osther K. - Cimetidine enhances IFN-induced augmentation of NK cell activity and suppresses IFN production. Acta Path. Microbiol. Immunol. Scand. (Sect. C), 1985, 93, 153-159.
74. Hirai N., Hattori N., Hill N.O., Osther K. - Antiviral and anti-proliferative activities of human leukocyte IFN potentiated by cimetidine in vitro. J. Interferon Res., 1985, 5, 375-382.
75. Holmgren H., Wohlfart G. - Mast cells in experimental rat sarcomas. Cancer Res., 1947, 7, 686-691.
76. Iken K., Cheng S., Fargin A. et al. - Serotonin upregulates mitogen-stimulated B lymphocyte proliferation through 5-HT1A receptors. Cell Immunol., 1995, 163, 1-9.
77. Jackson J.C., Cross R.J., Walker R.F. et al. - Influence of serotonin on the immune response. Immunol., 1985, 54, 504-512.
78. Jolles B., Greening S.G. - Effect of heparin upon tumor growth. Acta Ung. Int. Cancer, 1960, 16, 682-685.
79. Kheifets J., Thieme T., Mirkovich A., Ackerman N. - The effects of histamine and serotonin on polymorphonuclear leukocyte accumulation in the rat. Eur. J. Pharmacol., 1986, 128, 179-186.
80. Kierszenbaum F., Ackerman S.J., Gleich G.J. - Inhibition of antibody-dependent eosinophil-mediated cytotoxicity by heparin. J. Immunol., 1982, 128, 515-517.
81. Kikuchi Y., Oomori K., Kizawa I., Kato K. - Effects of cimetidine on tumor growth and immune function in nude mice bearing human ovarian carcinoma. J. Natl. Cancer Inst., 1985, 74, 495-498.
82. Kikuchi Y., Oomori K., Kizawa I., Kato K. - Augmented NK cell activity in ovarian cancer patients treated with cimetidine. Eur. J. Cancer Clin. Oncol., 1986, 22, 1037-1043.
83. Kikuchi Y., Kizawa I., Oomori K. et al. - Effects of cimetidine on IL-2 production by peripheral blood lymphocytes in advanced ovarian carcinomas. Eur. J. Cancer Clin. Oncol., 1988, 24, 1185-1190.
84. Koenig W. - Uber die bedentung von mastzellen in benzpyrentumor von ratten. Z. Exp. Med., 1955, 126, 64-72.
85. Kunkel S.L., Chensue S.W., Phan S.H. - Prostaglandins as endogenous mediators of IL-1 production. J. Immunol., 1986, 136, 186-192.
86. Kut J.L., Young M.R.I., Crayton J.W. et al. - Regulation of murine T-lymphocyte function by spleen-derived and exogenous serotonin. Immunopharmacol. Immunotoxicol., 1992, 14, 783-796.
87. Lala P.K. - Indomethacin therapy abrogates the prostaglandin-mediated suppression of natural killer cell activity in tumor-bearing mice and prevents tumor metastasis. Cell. Immunol., 1986, 99, 108-118.
88. Lang I., Török K., Gergely P. et al. - Effect of histamine receptor blocking on human antibody-dependent cell-mediated cytotoxicity. Scand. J. Immunol., 1981, 13, 361-366.
89. Langford M.P., Lett-Brown M.A., Stanton J.G., Grant J.A. - Histamine-releasing activity (HRA) produced by leukocytes cocultured with tumor cells. Immunol. Invest., 1987, 16, 129-138.
90. Lespinats G., Bonnet M., Thouzeau S., Burtin C. - Enhancement by serotonin of intra-tumour penetration of spleen cells. Br. J. Cancer, 1984, 50, 545-547.
91. Liu C.M. - Immune regulation of the L 5178 Y murine tumor dormant stage. I : in vivo and in vitro effects of PGE2 and indomethacin on tumor cell growth. J. Exp. Med., 1986, 164, 1259-1273.
92. Loesel L.S. - IgE immunopathologic findings in Hodgkin's disease. Appl. Immunohistochem., 1994, 2, 123-129.
93. Los G., De Weger R.A., Van den Berg D.T.W.M. et al. - Macrophage infiltration in tumors and tumor-surrounding tissue: influence of serotonin and sensitized lymphocytes. Cancer Immunol. Immunother., 1988, 26, 145-152.
94. Lynch N.R., Salomon J.C. - Passive local anaphylaxis. Demonstration of antitumoral activity and complementation of intratumoral BCG. J. Natl. Cancer Inst., 1977, 58, 1093-1098.
95. Mac Kay W.D. - The incidence of allergic disorders and cancer. Br. J. Cancer, 1966, 20, 434-437.
96. Mahapatro R.C., Bowers H.M. - Distribution of mast cells in the axillary lymph nodes of breast cancer patients. Cancer, 1979, 44, 592-597.
97. Manda T., Nishigaki F., Mori J., Shimomura K. - Important role of serotonin in the antitumor effects of recombinant tumor necrosis factor-α in mice. Cancer Res., 1988, 48, 4250-4255.
98. Manning L.S. - Indomethacin augments lymphokine-activated killer cell generation by patients with malignant mesothelioma. Clin. Immunol. Immunopathol., 1989, 53, 68-77.
99. Marom Z. - Mast cells and their mediators. Ann. Allergy, 1983, 50, 367-372.
100. Maslinski C., Kierska D., Sasiak K., Adamas B. - Histamine and its catabolism in tumor-bearing rat and mouse. Agents Actions, 1984, 14, 497-500.
101. Maslinski C., Kierska D. - Histamine in C3H/W mice carrying spontaneous tumors of the mammary gland. Agents Actions, 1991, 33, 192-194.
102. McDuffie H.H. - Atopy and primary lung cancer. Histology and sex distribution. Chest, 1991, 99, 404-407.
103. McWorther W.P. - Allergy and risk of cancer. A prospective study using NHANESI follow-up data. Cancer, 1988, 62, 451-455.
104. Mertens W.C., Bramwell V.H.C., Gwadry-Sridhar F. et al. - Effect of indomethacin plus ranitidine in advanced melanoma patients on high dose interleukin-2. Lancet, 1992, 340, 397-398.
105. Möller H., Mellemgaard A. - Prostate cancer incidence in cimetidine users. J. Natl. Cancer Inst., 1992, 84, 359-360.
106. Möller H., Lindvig K., Klefter R. et al. - Cancer occurence in a cohort of patients treated with cimetidine. Gut, 1989, 30, 1558-1562.
107. Möller H., Nissen A., Mosbech J. - Use of cimetidine and other peptic ulcer drugs in Denmark 1970-1990 with analysis of the risk of gastric cancer among cimetidine users. Gut, 1992, 33, 1166-1169.
108. Moriarty C.M., Stucky J.L., Hamburger K.W. et al. - Blood histamine and solid malignant tumors. J. Cancer Res. Clin. Oncol., 1988, 114, 588-592.
109. Nair M.P.N., Cilik J.M., Schwartz S.A. - Histamine-induced suppressor factor inhibition of NK cells: reversal with interferon and interleukin-2. J. Immunol., 1986, 136, 2456-2462.
110. Nakajima I., Chu T.M. - Synergistic antitumor activity of interleukin-2 and cimetidine against syngeneic murine tumor. Cancer Immunol. Immunother., 1991, 33, 9-14.
111. Nolte H., Pedersen L., Mouridsen H.T. - Combined treatment of advanced malignant melanoma with coumarin and cimetidine. Anticancer Res., 1987, 7, 449-450.
112. Nordlund J.J., Askenase P.W. - The effect of histamine, anti-histamines, and a mast cell stabilizer on the growth of Cloudman melanoma cells in DBA/2 mice. J. Invest. Dermatol., 1983, 81, 28-31.
113. v/+, W/+, +/+) grafted with a methylcholanthrene-induced sarcoma. Correlation with tumor rejection. Cancer Lett., 1994, 85, 125-131.
114. Pope B.L. - The effect of indomethacin on the activation and effector function of suppressor cells from tumor-bearing mice. Cancer Immunol. Immunother., 1985, 19, 101-108.
115. Riley J.F. - Mast cells and cancer in the skin of mice. Lancet, 1966, 2, 1457-1459.
116. Roche W.R. - Mast cells and tumors. The specific enhancement of tumor proliferation in vitro. Am. J. Pathol., 1985, 119, 57-64.
117. Rogers T.J., Campbell L., Calhoun K. et al. - Suppression of B-cell and T-cell responses by the prostaglandin-induced T-cell-derived suppressor (PITS). I : analysis of the PITSβ factor. Cell. Immunol., 1982, 66, 279-276.
118. Rola-Plesczynski M., Borgeat P., Sirois P. - Leukotriene B4 induces human suppressor lymphocytes. Biochem. Biophys. Res. Commun., 1984, 108, 1531-1537.
119. Rosenbaum J.T., Dwyer J.M. - The role of IgE in the immune response to neoplasia. A review. Cancer, 1977, 39, 11-15.
120. Ruiz-Arguelles A., Seroogy K.B., Ritts R.E. - In vitro effect of cimetidine on human cell-mediated cytotoxicity. I - Inhibition of natural killer cell cytotoxicity. Cell. Immunol., 1982, 69, 1-12.
121. Scheinmann P., Lebel B., Lynch N.R. et al. - Histamine levels in blood and other tissues of male and female C3H mice. II: mice carrying a 3-methylcholanthrene-induced tumor. Agents Actions, 1979, 9, 95-96.
122. + T cells by interleukin-2 and cimetidine. Int. Arch. Allergy Appl. Immunol., 1992, 97, 8-16.
123. Skolnick G., Ivarsson L., Bagge U. - The influence of antiserotonin treatment with ketanserin on the pulmonary lodgment of circulating tumour cells in normal and traumatized rats. Eur. J. Cancer Clin. Oncol., 1983, 19, 843-846.
124. Slauson D.O., Walker C., Kristensen F. et al. - Mechanisms of serotonin-induced lymphocyte proliferation inhibition. Cell. Immunol., 1984, 84, 240-252.
125. Sonoda T., Tsuyama K., Kitamura Y., Tanooka H. - Different effects of DMBA and TDNP acetate on differentiation of mast cells in the skin of mice. Am. J. Pathol., 1982, 106, 312-317.
126. Starkey J.R., Crowle P.K., Taubenberger S. - Mast cell-deficient W/Wv mice exhibit a decreased rate of tumor angiogenesis. Int. J. Cancer, 1988, 42, 48-52.
127. Steffen M., Abboud M., Potter G.K. et al. - Presence of tumor necrosis or a related factor in human basophil/mast cells. Immunology, 1983, 66, 445-450.
128. Sternberg E.M., Trial J., Parker C.W. - Effect of serotonin on human macrophages. Suppression of Ia expression by serotonin and its reversal by 5-HT2 serotoninergic receptor antagonists. J. Immunol., 1986, 137, 276-282.
129. Suonio E., Tuomisto L. - Effect of metoprine on human ovarian cancer in the mouse subrenal capsule assay (SRCA). In: new perspectives in histamine research. Proc. of the satellite symposium of the XIth international congress of pharmacology of IUPHAR, July 6-8, 1990, Noordwijherhout (Netherlands), p. 80 (P 41).
130. Suonio E., Tuomisto L., Alhava E. - Effects of histamine, H1, H2 and Hie receptor antagonists and α-fluoromethylhistidine on the growth of human colorectal cancer in the subrenal capsule assay. Agents Actions, 1994, 41, C118-C120.
131. Tanaka Y. - Antitumor activity of indomethacin in mice bearing advanced colon-26 carcinoma compared with those with early transplants. Cancer Res., 1989, 49, 5935-5939.
132. Tanooka H., Kitamura Y., Sado T. et al. - Evidence for involvement of mast cells in tumor suppression in mice. J. Natl. Cancer Inst., 1982, 69, 1305-1308.
133. Tharp M.D., Kasper C., Thiele D. et al. - Studies of connective-tissue mast cell-mediated cytotoxicity. J. Invest. Dermatol., 1989, 93, 423-428.
134. Tonnesen H., Bulow S., Fischerman K. et al. - Effect of cimetidine on survival after gastric cancer. Lancet, 1988, 330, 990-992.
135. Ucar K. - The effects of histamine H2 receptor antagonists on melanogenesis and cellular proliferation in melanoma cells in culture. Biochem. Biophys. Res. Commun., 1991, 177, 545-550.
136. Ueda T., Aozaka K., Tsujimoto M. et al. - Pronostic significance of mast cells in soft tissue sarcoma. Cancer, 1988, 62, 2416-2419.
137. Van Loveren H.V., Den Otter W., Meade R. et al. - A role for mast cells and the vasoactive amine serotonin in T cell-dependent immunity to tumors. J. Immunol., 1985, 134, 1292-1299.
138. Villata F., Kierszenbaum F. - Role of inflammatory cells in Chagas' disease. 1: uptake and mechanism of destruction of intracellular (amastigote) forms of Trypanosoma cruzi by human eosinophils. J. Immunol., 1984, 132, 2053-2058.
139. Wlodarski K., Kukwa A., Beaton O. et al. - Decrease of mast cells in the stroma of human cancer. Arch. Immunol. Ther. Expt, 1983, 31, 261-266.
140. Yamamoto H., Fuyama S., Arai S., Sendo F. - Inhibition of mouse natural killer cells by heparin. Cell. Immunol., 1985, 96, 409-417.
141. Young M.R., Knies S. - PGE production by Lewis lung carcinoma. Mechanism for tumor establishment in vivo. J. Natl. Cancer Inst., 1984, 72, 919-925.
142. Young M.R. - Suppressor alveolar macrophages in mice bearing metastatic lung carcinoma tumors. J. Leukocyte Biol., 1987, 42, 682-688.